Clinical trial
Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various…
NCT00050687 · Titan Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00050687 |
|---|---|
| Title | Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies |
| Official title | A Randomized, Serum Level-targeted Study Investigating the Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Patients With Various Refractory Malignancies |
| Lead sponsor | Titan Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms, Multiple Myeloma, Bladder Neoplasms, Lymphoma |
| Intervention type | Drug |
| Interventions | Gallium maltolate |
| Start date | Jun 1, 2001 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | Dec 19, 2002 |
| Last update posted | Jan 28, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: